Last reviewed · How we verify
Hyperpolarized C13
At a glance
| Generic name | Hyperpolarized C13 |
|---|---|
| Also known as | HP [1-13C]pyruvate |
| Sponsor | Ivan de Kouchkovsky, MD |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hyperpolarized Imaging in Diagnosing Participants With Glioma (PHASE1)
- Hyperpolarized 13C Pyruvate MRI Scan in Predicting Tumor Aggressiveness in Patients With Renal Tumors (PHASE2)
- Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance (PHASE2)
- Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors (PHASE1)
- Hyperpolarized Carbon-13 Alpha-ketoglutarate Imaging in IDH Mutant Glioma (EARLY_PHASE1)
- An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer and Other Malignancies of the Head and Neck Undergoing Radiation Therapy and/or Systemic Therapy (PHASE1)
- Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
- Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Hyperpolarized C13 CI brief — competitive landscape report
- Hyperpolarized C13 updates RSS · CI watch RSS
- Ivan de Kouchkovsky, MD portfolio CI